

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Aggrega Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC
Details : Breckenridge previously launched Succinylcholine Chloride Injection, USP, 20mg/mL under this agreement, which is now available from Breckenridge as a carton of 25 vials.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Aggrega Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dr. Reddy's Laboratories has launched Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the USFDA.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP
Details : Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S. FDA has approved Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL Multiple-Dose Vial. Amphastar’s drug product was determined by the FDA to be therapeutically equivalent to Succinylcholine Chloride Inje...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2020
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparing Intubating Conditions Using Succinylcholine or Rocuronium for Rigid Bronchoscopy
Details : Succinylcholine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Myalgia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 27, 2013
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Low Dose Mivacurium vs. Low Dose Succinylcholine for Rigid Bronchoscopy
Details : Succinylcholine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Myalgia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2013
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Muscle Relaxation for Short Procedures
Details : Succinylcholine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Fasciculation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2013
Lead Product(s) : Succinylcholine Chloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable



